Protox Therapeutics Inc. (“Protox”, TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced that it has entered into a US $15 million loan agreement ...

Warburg Pincus has committed to invest CDN$35 million in Protox, which develops receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer. Warburg is a global PE firm.

Canada's Protox Therapeutics has landed a $75 million development and commercialization agreement with Japan-based Kissei Pharmaceutical. The $75 million deal covers PRX302, Protox's PSA-activated pro ...

Protox Therapeutics Signs $75 Million License Agreement with Kissei Pharmaceutical Co., Ltd. for Commercialization of PRX302 in Japan for BPH and Prostate Disease VANCOUVER, April 29 /CNW/ - Protox ...

Shareholders of Vancouver-based Protox Therapeutics Inc. (TSX:PRX) have approved multi-stage financing that could see a global private equity firm become the company’s majority shareholder. Under the ...

Protox Therapeutics Inc., which develops treatments for urological diseases, said Warburg Pincus has agreed to invest another C$8.3 million in the company. Under the terms of a 2010 agreement, Warburg ...

It's not easy keeping a poker face. I mean there are so many times when I meet people and it would be beneficial to keep a straight face, but sometimes it's just so hard! When a patient tells me they ...

PRX302 is currently in North American Phase II evaluation as PSA-activated pore-punching prodrug. Kissei Pharamaceutical is paying Protox Therapeutics $3 million up front for exclusive Japanese rights ...

VANCOUVER – Protox Therapeutics Inc. (TSX:PRX), a developer of drugs to treat urological diseases, said Monday it has entered into a US $15 million loan agreement with a U.S. lender to help the ...

VANCOUVER, June 2 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo ...

VANCOUVER, Aug. 11 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended ...